Antibody-Drug Conjugates (ADCs) is a highly contested area in drug discovery and development. There are currently more than 50 clinical programs across pharmaceutical and biotech companies. This exciting field has seen significant advancements in various aspects of ADCs (linkers, payloads and antibodies) in the last 20-30 years. However, it remains a challenge for database systems to handle ADCs effectively and efficiently due to the complexity of such molecular entities. In this webinar, we will discuss how ADCs and their components are managed in Scilligence’s integrated informatics platform using our proprietary technology or HELM (Hierarchical Editing Language for Macromolecules) invented at Pfizer.





About the Speaker:

Dr. Jinbo Lee, Scilligence's CSO, is an expert in research informatics with extensive experiences in drug discovery and development. As the prior Head of Chemistry at Ensemble Therapeutics, he was responsible for medicinal, process, and analytical chemistry; molecule modeling; and cheminformatics. Dr. Lee has many publications in prestigious scientific journals and holds a number of patents.

